Global Human Microbiome Market: The Role of Microbiome Diagnostics in Achieving 31% CAGR Growth by 2030
The human microbiome market is projected to grow at a CAGR of 31% over the forecast period. Major factors driving growth include advancement in microbiome sequencing technology, increasing number of biotech startups exploring microbiome therapies, growing collaboration between organizations and academia in microbiome industry, growing investment in microbiome research and therapeutics by public and private organizations, rising incidence of chronic and lifestyle-related diseases, and shift towards preventive and personalized medicines.
The human microbiome refers to the diverse community of
microorganisms such as bacteria, viruses, fungi, archaea, eukaryotes, and other
microbes that live in and on the human body. These microbes are found in
various areas, including the gut, skin, mouth, respiratory system, and other
mucosal surfaces, where they play a vital role in maintaining health and
supporting essential bodily functions. Initially, it was believed that the
microbiome contained approximately 100 times more genes than the human genome,
but further research has adjusted this estimate to about ten times more. While
these microbes are typically not harmful, they are crucial for our well-being.
For example, they produce vitamins that our bodies cannot synthesize, help
break down food to extract necessary nutrients, train our immune systems to
identify harmful pathogens, and even generate anti-inflammatory compounds that
combat disease-causing microbes.
To request a free sample copy of this report, please
visit below https://meditechinsights.com/global-human-microbiome-market/request-sample/
Advancements in microbiome research and technologies
driving market growth
The rapid pace of scientific advancements in microbiome
research is one of the most significant drivers of the human microbiome market.
The increasing understanding of the microbiome's role in human health
particularly its influence on immunity, metabolism, mental health, and disease
is catalyzing innovation in microbiome-based therapies, diagnostics, and
products. More than 100 trillion microorganisms live in the human body, and
their interactions with host cells are complex. Ongoing research is revealing how
the microbiome can influence disease onset, progression, and treatment
outcomes, spurring the development of new therapeutic strategies, personalized
medicine, and consumer products like probiotics and prebiotics. As technology
improves and more studies are conducted, the potential for microbiome-based
solutions to transform disease prevention, treatment, and overall well-being
continues to grow.
Increasing investments in microbiome-based therapies and
diagnostics by pharmaceutical companies and biotechnology firms propel market
growth
Recent advancements in sequencing technologies and synthetic
biology have confirmed the connection between the microbiome and various
diseases, leading to a surge in research funding and investment in
microbiome-related therapeutics, diagnostics, and products. Investments in
microbiome-focused startups is expected to rise, as venture capitalists and
pharma companies aim to capitalize on the promising potential of
microbiome-based therapeutics and diagnostics. For example, venture capital
investments in microbiome startups reached record levels, reflecting growing
confidence in the sector's future. This influx of capital is driving the
commercialization of microbiome-based therapeutics, including FMT,
microbiome-modulating drugs, and innovative probiotics, while also expanding
clinical trials on the microbiome's impact on various diseases. As per the
article published by strategy& (part of PwC group) there were 43 VC-backed
deals valued at $321 million in 2022. North America and Europe remain the leading
regions for microbiome funding, though investment is also growing in the
Asia-Pacific region.
Key Constraints/Challenges
The market is confronted with challenges such as scientific
and regulatory barriers, as well as a lack of standardization due to the use of
numerous microbial strains that are difficult to distinguish. Additionally,
there is a limited public understanding and a need for education to highlight
the broad health benefits offered by products containing these bacteria.
Competitive Landscape Analysis
The global human microbiome market is marked by the presence
of established and emerging market players such as OpenBiome; Bayers
AG; Danone; Nestle, Seres Therapeutics Inc.; Ferring
Pharmaceuticals; Enterome SA; Finch Therapeutics Group,
Inc.; Biomebank, Microbiotica; Seeds Health, Inc.; Synlogic; and Vedanta
Bioscience, Inc. among others. Some of the key strategies adopted
by market players include new product development, strategic partnerships and
collaborations, and investments.
🔗 Want deeper insights? Download the
sample report here:
https://meditechinsights.com/global-human-microbiome-market/request-sample/
Market Segmentation
This report by Medi-Tech Insights provides the size of
the global human microbiome market at the regional- and country-level from
2023 to 2030. The report further segments the market based on product, disease,
type, and end-user.
- Market
Size & Forecast (2023-2030), By Product, USD Million
- Drugs
- Prebiotics
- Probiotics
- Synbiotics
- Market
Size & Forecast (2023-2030), By Disease, USD Million
- Infectious
Diseases
- Gastrointestinal
Diseases
- Endocrine
and Metabolic Disorders
- Other
Diseases
- Market
Size & Forecast (2023-2030), By Type, USD Million
- Bacterial
Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT)
- Live
Bio therapeutic Products
- Other
Types
- Market
Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
& Clinics
- Long-Term
Care Facilities
- Others
- Market
Size & Forecast (2023-2030), By Region, USD Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment